0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Selective blockade of Ca v1.2 (α1C) versus Ca v1.3 (α1D) L-type calcium channels by the black mamba toxin calciseptine

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          L-type voltage-gated calcium channels are involved in multiple physiological functions. Currently available antagonists do not discriminate between L-type channel isoforms. Importantly, no selective blocker is available to dissect the role of L-type isoforms Ca v1.2 and Ca v1.3 that are concomitantly co-expressed in the heart, neuroendocrine and neuronal cells. Here we show that calciseptine, a snake toxin purified from mamba venom, selectively blocks Ca v1.2 -mediated L-type calcium currents (I CaL) at concentrations leaving Ca v1.3-mediated I CaL unaffected in both native cardiac myocytes and HEK-293T cells expressing recombinant Ca v1.2 and Ca v1.3 channels. Functionally, calciseptine potently inhibits cardiac contraction without altering the pacemaker activity in sino-atrial node cells, underscoring differential roles of Ca v1.2− and Ca v1.3 in cardiac contractility and automaticity. In summary, calciseptine is a selective L-type Ca v1.2 Ca 2+ channel blocker and should be a valuable tool to dissect the role of these L-channel isoforms.

          Abstract

          L-type voltage-gated calcium channels are involved in multiple physiological functions. Here the authors identify calciseptine, a toxin purified from black mamba venom, as a selective inhibitor of Ca v1.2 L-type Ca 2+ channels.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Cardiac excitation-contraction coupling.

          Of the ions involved in the intricate workings of the heart, calcium is considered perhaps the most important. It is crucial to the very process that enables the chambers of the heart to contract and relax, a process called excitation-contraction coupling. It is important to understand in quantitative detail exactly how calcium is moved around the various organelles of the myocyte in order to bring about excitation-contraction coupling if we are to understand the basic physiology of heart function. Furthermore, spatial microdomains within the cell are important in localizing the molecular players that orchestrate cardiac function.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential

            Voltage-gated calcium channels are required for many key functions in the body. In this review, the different subtypes of voltage-gated calcium channels are described and their physiologic roles and pharmacology are outlined. We describe the current uses of drugs interacting with the different calcium channel subtypes and subunits, as well as specific areas in which there is strong potential for future drug development. Current therapeutic agents include drugs targeting L-type Ca(V)1.2 calcium channels, particularly 1,4-dihydropyridines, which are widely used in the treatment of hypertension. T-type (Ca(V)3) channels are a target of ethosuximide, widely used in absence epilepsy. The auxiliary subunit α2δ-1 is the therapeutic target of the gabapentinoid drugs, which are of value in certain epilepsies and chronic neuropathic pain. The limited use of intrathecal ziconotide, a peptide blocker of N-type (Ca(V)2.2) calcium channels, as a treatment of intractable pain, gives an indication that these channels represent excellent drug targets for various pain conditions. We describe how selectivity for different subtypes of calcium channels (e.g., Ca(V)1.2 and Ca(V)1.3 L-type channels) may be achieved in the future by exploiting differences between channel isoforms in terms of sequence and biophysical properties, variation in splicing in different target tissues, and differences in the properties of the target tissues themselves in terms of membrane potential or firing frequency. Thus, use-dependent blockers of the different isoforms could selectively block calcium channels in particular pathologies, such as nociceptive neurons in pain states or in epileptic brain circuits. Of important future potential are selective Ca(V)1.3 blockers for neuropsychiatric diseases, neuroprotection in Parkinson's disease, and resistant hypertension. In addition, selective or nonselective T-type channel blockers are considered potential therapeutic targets in epilepsy, pain, obesity, sleep, and anxiety. Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions. Thus, more selective calcium channel blockers hold promise for therapeutic intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism.

              Ca(V)1.2, the cardiac L-type calcium channel, is important for excitation and contraction of the heart. Its role in other tissues is unclear. Here we present Timothy syndrome, a novel disorder characterized by multiorgan dysfunction including lethal arrhythmias, webbing of fingers and toes, congenital heart disease, immune deficiency, intermittent hypoglycemia, cognitive abnormalities, and autism. In every case, Timothy syndrome results from the identical, de novo Ca(V)1.2 missense mutation G406R. Ca(V)1.2 is expressed in all affected tissues. Functional expression reveals that G406R produces maintained inward Ca(2+) currents by causing nearly complete loss of voltage-dependent channel inactivation. This likely induces intracellular Ca(2+) overload in multiple cell types. In the heart, prolonged Ca(2+) current delays cardiomyocyte repolarization and increases risk of arrhythmia, the ultimate cause of death in this disorder. These discoveries establish the importance of Ca(V)1.2 in human physiology and development and implicate Ca(2+) signaling in autism.
                Bookmark

                Author and article information

                Contributors
                pietro.mesirca@igf.cnrs.fr
                joel.nargeot@igf.cnrs.fr
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                2 January 2024
                2 January 2024
                2024
                : 15
                : 54
                Affiliations
                [1 ]GRID grid.121334.6, ISNI 0000 0001 2097 0141, Institut de Génomique Fonctionnelle, , Université de Montpellier, CNRS, INSERM, ; 34094 Montpellier, France
                [2 ]Laboratory of Excellence Ion Channels, Science & Therapeutics, F-06560 Valbonne, France
                [3 ]GRID grid.10223.32, ISNI 0000 0004 1937 0490, Department of Physiology, Faculty of Medicine Siriraj Hospital, , Mahidol University, ; Bangkok, Thailand
                [4 ]GRID grid.429194.3, ISNI 0000 0004 0638 0649, Université Côte d’Azur, CNRS, IPMC (Institut de Pharmacologie Moléculaire et Cellulaire), FHU InovPain (Fédération Hospitalo-Universitaire “Innovative Solutions in Refractory Chronic Pain”), ; F-06560 Valbonne, France
                [5 ]Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, ( https://ror.org/01tgyzw49) Singapore, Singapore
                Author information
                http://orcid.org/0000-0002-9538-3096
                http://orcid.org/0000-0003-1632-7318
                http://orcid.org/0000-0002-0876-0325
                http://orcid.org/0000-0002-8892-3373
                http://orcid.org/0000-0003-2893-5636
                Article
                43502
                10.1038/s41467-023-43502-w
                10762068
                38167790
                249deeaa-1246-4f10-b1b6-e1c8003847f0
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 21 April 2023
                : 10 November 2023
                Funding
                Funded by: LABEX-ICST Laboratory of Excellence Ion Channel Science and Therapeutics
                Funded by: FundRef https://doi.org/10.13039/501100001674, Fondation Leducq;
                Award ID: 19CV03
                Award ID: 19CV03
                Award Recipient :
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2024

                Uncategorized
                physiology,biophysics,calcium channels,electrophysiology
                Uncategorized
                physiology, biophysics, calcium channels, electrophysiology

                Comments

                Comment on this article